A Clinical Study of MK-7262 and Enlicitide in Healthy Participants (MK-7262-003)

Purpose

The goal of this study is to learn what happens to a single dose of enlicitide over time in a healthy participant's body when the participant is given a single dose of MK-7262 and what happens to a single dose of MK-7262 over time in a healthy participant's body when the participant is given a single dose of enlicitide.

Condition

  • Healthy

Eligibility

Eligible Ages
Between 19 Years and 55 Years
Eligible Sex
All
Accepts Healthy Volunteers
Yes

Inclusion Criteria

The main inclusion criteria include but are not limited to the following: - Is in good health before randomization - Has a body mass index (BMI) ≥18 and ≤32 kg/m^2, inclusive

Exclusion Criteria

The main exclusion criteria include but are not limited to the following: - Has a history or presence of clinically significant medical or psychiatric condition or disease - Has a history of cancer

Study Design

Phase
Phase 1
Study Type
Interventional
Allocation
Randomized
Intervention Model
Crossover Assignment
Primary Purpose
Basic Science
Masking
None (Open Label)

Arm Groups

ArmDescriptionAssigned Intervention
Experimental
MK-7262 		Participants will receive MK-7262 orally.
  • Drug: MK-7262
    Oral administration
Experimental
Enlicitide 		Participants will receive enlicitide orally.
  • Drug: Enlicitide
    Oral administration
    Other names:
    • enlicitide decanoate
    • MK-0616
Experimental
MK-7262 plus Enlicitide 		Participants will receive MK-7262 and enlicitide orally.
  • Drug: MK-7262
    Oral administration
  • Drug: Enlicitide
    Oral administration
    Other names:
    • enlicitide decanoate
    • MK-0616

Recruiting Locations

Celerion ( Site 0001)
Lincoln, Nebraska 68502
Contact:
Study Coordinator
402-476-2811

More Details

Status
Recruiting
Sponsor
Merck Sharp & Dohme LLC

Study Contact

Toll Free Number
1-888-577-8839
Trialsites@msd.com